Plasma neuregulin 1 as a synaptic biomarker in Alzheimer’s disease

Background Synaptic dysfunction is an early core feature of Alzheimer’s disease (AD), closely associated with cognitive symptoms. Neuregulin 1 (NRG1) a growth and differentiation factor key role in the development maintenance synaptic transmission. Previous reports have shown that changes cerebrospinal fluid (CSF) NRG1 concentration are status biomarker evidence AD pathology. Plasma biomarkers reflecting impairment would be great clinical interest. Our oubjective was to measure plasma patients comparison other neurodegenerative disorders neurological controls (NC) study its association biomarkers. Method This retrospective enrolled 127 participants including at mild stage (AD-MCI, n = 27) dementia (n 35), non-AD 26, Aβ-negative), MCI 19) 20). CSF NRG1, as well (Aβ 42/Aβ 40 ratio, phospho-tau total tau), were measured using ELISA. markers ELISA for GAP-43 neurogranin through immunoprecipitation mass spectrometry SNAP-25. Result higher AD-MCI compared (respectively P 0.005 P<0.001). differentiated from area under curve 88.3%, NC 87.3%. correlated (β 0.372, 0.0056, adjusted on age sex). whole cohort Aβ-positive -0.197- 0.423). GAP-43, SNAP-25 0.278-0.355). inversely MMSE (all, β -0.188, 0.038; Aβ+: -0.255, 0.038). Conclusion increased correlates biomarkers, status. Thus, promising non-invasive monitor AD.